Jean Rommelaere

German Cancer Research Center — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

54h-index9.3kcitations356works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(282), Parvovirus B19 Infection Studies(122), Animal Virus Infections Studies(109), CAR-T cell therapy research(74), RNA Interference and Gene Delivery(49)

Publications356 total

H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma
Cancers·2024· 2 citedOpen Access
The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics
Pathogens·2024· 3 citedOpen Access
The Multifaceted Role of Protoparvoviruses in Human Cutaneous T Cell Lymphoma: From Candidate Causative Agents to Potential Oncolytic Virus Therapeutics
Preprints.org·2024· 1 citedOpen Access
Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells
Pathogens·2023· 8 citedOpen Access
Supplementary Table 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Table 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Data from Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV
2023Open Access
Supplementary Table 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Data from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Data from Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV
2023Open Access
Data from Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV
2023Open Access
Data from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
page 1 of 18Next →

Frequent Co-authors

Johnny Cornelis(13), Christiane Dinsart(9), Karsten Geletneky(6), Assia L. Angelova(6), Antonio Marchini(6), Celina Cziepluch(6), Barbara Leuchs(5), Laurent Daeffler(5), Zahari Raykov(5), Marc Aprahamian(4), Nathalia A. Giese(4), Jo Van Damme(4), Nathalie Salomé(4), Irina Kiprianova(3), Annick Brandenburger(3), Joerg R. Schlehofer(3), Marta Herrero y Calle(3), Laurent Deleu(3), Daniel Legendre(3), Bernard Avalosse(3)